Patents Examined by Rebecca Cook
  • Patent number: 7109244
    Abstract: Investigation of the activity of extracts of the clam Spisula polynyma has led to antitumor long-chain, straight-chain alkane or alkene compounds which have a 2-amino group and a 3-hydroxy group. The present invention is directed to compositions and methods comprising an isolated and purified long-chain, straight-chain 2-amino-3-hydroxyalkane, or prodrug thereof, and a pharmaceutically acceptable carrier, wherein the carbon chain in the long-chain, straight-chain 2-amino-3-hydroxyalkane is C16–C24.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: September 19, 2006
    Inventors: Kenneth L. Rinehart, Robert A. Warwick, Jesus Avila, Nancy L. Fregeau Gallagher, Dolores Garcia Gravalos, Glynn T. Faircloth
  • Patent number: 7078395
    Abstract: There is provided use of a cyclic compound or a pharmaceutically active salt thereof in the manufacture of a medicament to prevent and/or inhibit and/or arrest cell cycling, wherein the cyclic compound comprises at least one ring, wherein Group I and Group II, independently of each other, are attached to a ring of the cyclic compound; wherein Group I is a hydrocarbyl or an oxyhydrocarbyl group; and wherein Group II is a group of the formula X is P or S; when X is P, Y is ?O or S, Z is —OH and R is hydrocarbyl or H; when X is S, Y is ?O, Z is ?O, and R is hydrocarbyl or N(R1)(R2), wherein each of R1 and R2 is independently selected from H or a hydrocarbyl group.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: July 18, 2006
    Assignee: Sterix Limited
    Inventors: Michael John Reed, Barry Victor Lloyd Potter
  • Patent number: 7071230
    Abstract: Methods of preventing or reducing hearing or balance loss and damage to ear cells in patients who have been exposed to toxic levels of noise are provided. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to exposure to noise. Combinations of these time periods can also be employed.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: July 4, 2006
    Assignee: Board of Trustees of Southern Illinois University
    Inventor: Kathleen C. M. Cambpell
  • Patent number: 7071232
    Abstract: The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same in the field of general health care, for example, to improve resistance to stress, improve production of desired characteristics or useful products in animals, to increase weight gain, prevent diseases caused by pathogens, and to decrease feed efficiency. The invention has applications in the field of animal husbandry, and in treating or preventing weight loss associated with a disease in humans. It also relates to administering carbobenzoxy beta-alanyl taurine to improve feed efficiency in an animal, comprising administering to the animal an amount of carbobenzoxy beta-alanyl taurine sufficient to reduce the amount of food required to increase a unit of weight in the animal.
    Type: Grant
    Filed: August 14, 2000
    Date of Patent: July 4, 2006
    Inventor: Floyd E. Taub
  • Patent number: 7067545
    Abstract: Remedies for spinocerebellar degeneration or compositions for treating the same which contain as the active ingredient one or more members selected from among D-cycloserine, D-serine esters, D-serine and salts thereof. A method for treating spincerebellar degeneration which comprises administering to a patient with this disease in an efficacious dose of one or more members selected from among D-cycloserine, D-serine esters, D-serine and salts thereof.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: June 27, 2006
    Assignee: Meiji Seika Kaisha Ltd.
    Inventors: Keiji Wada, Toru Nishikawa, Yasuyuki Ichimaru, Aiko Sawa, Toyakazu Hiranuma
  • Patent number: 7064138
    Abstract: Methods for the prophylaxis, treatment, or management of irritable bowel syndrome using (?) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer are disclosed.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: June 20, 2006
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Patent number: 7053074
    Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: May 30, 2006
    Assignee: New Life Pharmaceuticals, Inc.
    Inventors: Gustavo C. Rodriguez, Regina Salas Whitaker
  • Patent number: 7026353
    Abstract: A method of inhibiting the growth of a Gram positive bacterium, the method comprising treating the bacterium with an effective amount of one or more furanones having the Formula as set out in the Figure, wherein the effective amount of the one or more furanones does not substantially adversely effect the survival of an animal cell when exposed to the one or more furanones
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: April 11, 2006
    Assignee: Unisearch Limited, A.C.N.
    Inventors: Staffan Kjelleberg, Peter David Steinberg, Carola Holmstrom, Arthur Back
  • Patent number: 7026343
    Abstract: The c-Myc oncoprotein, a helix-loop-helix-leucine zipper (HLH-ZIP) transcription factor, is frequently deregulated in human cancers. All known functions of c-Myc, including those pertaining to transformation, require that it heterodimerize with another HLH-ZIP protein, Max. Using a high throughput yeast-based assay, we identified seven low molecular weight substances that inhibit c-Myc-Max association. Each compound also prevented this interaction in vitro and inhibited the growth of c-Myc-expressing fibroblasts, although not of fibroblasts lacking c-Myc. Finally, short-term exposure of c-Myc over expressing fibroblasts to several of the compounds markedly reduced their in vivo tumorigenicity. These studies suggest that yeast-based assays can be used to identify inhibitors of protein-protein interactions and that these frequently function in mammalian cells. The signature specificities of each of the c-Myc-Max compounds identified here further suggest synergistic in vivo function.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: April 11, 2006
    Assignee: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Edward V. Prochownik, Christine Giap, John S. Lazo, Xiaoying Yin
  • Patent number: 7022687
    Abstract: The present invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one antihistamine, such as, for example, azelastine and/or levocabastine, for simultaneous, sequential or separate administration in the local treatment of allergies and airway disorders, for example of allergic rhinitis (rhinoconjunctivitis).
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: April 4, 2006
    Assignee: Asta Medica AG
    Inventors: Istvan Szelenyl, Degenhard Marx, Sabine Heer, Juergen Engel
  • Patent number: 7015244
    Abstract: Sesquiterpene epoxide compounds (trichothecenes) and methods for administering such compounds by inhalation for chemical debridement of cells in the lungs of COPD patients are disclosed.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: March 21, 2006
    Inventor: Mark Zamoyski
  • Patent number: 7015241
    Abstract: An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): wherein the ring A represents a monocyclic or bicyclic aromatic ring which may be substituted, the ring B represents a 6-membered unsaturated hydrocarbon ring or a 6-membered unsaturated heterocyclic ring containing one nitrogen atom as a heteroatom, each of which may be substituted, the ring C represents a 5-membered heterocyclic ring containing one or two nitrogen atoms, which may be substituted, W represents a single bond or —CH?CH—, X represents —N(R1)— or an oxygen atom, Y represents a carbon atom or a nitrogen atom, Z represents —N(R2)— or a nitrogen atom, and R1 and R2 may be identical or different and each represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, or a hydrate thereof.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: March 21, 2006
    Assignee: Eisai Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Takayuki Hida, Norimasa Miyamoto, Takeshi Nagasu, Tatsuo Okauchi, Hiroshi Yoshino, Naoko Hata, Kentaro Yoshimatsu, Nozomu Koyanagi, Kyosuke Kito
  • Patent number: 7015251
    Abstract: This invention provides a method for increasing apoptosis in tumor cells and a method of decreasing a size of a tumor, said methods comprising contacting the tumor cells with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone. This invention also provides a method of treating cancer in a subject which comprises a method according to either of the above-described methods. This invention provides a method for treating cancer in a subject comprising administering to the subject an effective amount of at least one antitumor chemotherapeutic agent and an effective amount of at least one ceramide, sequentially or concomitantly.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: March 21, 2006
    Assignee: Roger Williams Hospital
    Inventors: Harold J. Wanebo, Shashikant Mehta
  • Patent number: 7012091
    Abstract: Sesquiterpene epoxide compounds (trichothecenes) and methods for administering such compounds by inhalation to inhibit inflammatory responses in the respiratory tract are disclosed.
    Type: Grant
    Filed: October 25, 2003
    Date of Patent: March 14, 2006
    Inventor: Mark Zamoyski
  • Patent number: 7012098
    Abstract: Agents and methods for chemoprevention and treatment of neoplasia are described, the agents including a selective inhibitor of inducible nitric oxide synthase and a combination of a selective inhibitor of inducible nitric oxide synthase and an inhibitor of cylcooxygenase-2 in a pharmaceutical composition. The agents and methods are used for chemoprevention and treatment of neoplasia including colorectal cancer and other cancers affecting epithelial cells throughout the body. The agents can also be used to treat the fibrosis that occurs with radiation therapy, as well as adenomatous polyps, including those with familial adenomatous polyposis (FAP).
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: March 14, 2006
    Assignee: Pharmacia Corporation
    Inventors: Pamela T. Manning, Jane R. Connor, Karen Seibert, Chinthalapally V. Rao, Bandaru S. Reddy
  • Patent number: 7012087
    Abstract: The therapeutic use of temporary p53 inhibitors in the treatment of p53-mediated diseases, conditions, and injuries is disclosed.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: March 14, 2006
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Andrei V. Gudkov, Pavel G. Komarov, Elena A. Komarova
  • Patent number: 7008961
    Abstract: Carcinoma is treated in a patient by administration of Rhodamine-123 (Rh-123) orally or by intravenous injection of a treatment solution of Rh-123, ethyl alcohol, dextrose, and water in an amount sufficient to effect in vivo destruction of cancer cells. The treatment solution is made by mixing a stock solution of Rh-123 in a solution of 95% ethyl alcohol and 5% water (by volume) with a solution of 5% (by weight) dextrose in water. For prostate cancer, treatment is controlled by measuring the level of prostate specific antigen (PSA), or prostate specific acid phosphatase in the blood of the patient.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: March 7, 2006
    Assignee: Huntington Medical Research Institutes
    Inventors: Doris M. Arcadi, legal representative, John A. Arcadi, deceased
  • Patent number: 7008956
    Abstract: The therapeutic use of temporary p53 inhibitors in the treatment of p53-mediated diseases, conditions, and injuries is disclosed.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: March 7, 2006
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Andrei V. Gudkov, Pavel G. Komarov, Elena A. Komarova
  • Patent number: 7005447
    Abstract: A food product containing an effective amount of an active agent which is hydroxymatairesinol, a geometric isomer or stereoisomer thereof, or an acceptable salt thereof, or a mixture thereof, where the food product is selected from the group consisting of a nutritional supplement and a nutrient. The food product can increase the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on the administration of hydroxymatairesinol to the person.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: February 28, 2006
    Assignee: Hormos Nutraceutical Oy Ltd.
    Inventors: Markku Ahotupa, Christer Eckerman, Lauri Kangas, Sari Mäkelä, Niina Saarinen, Risto Santti, Anni Wärri
  • Patent number: RE39480
    Abstract: A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 ?g of chromium and between 25 ?g and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: January 23, 2007
    Assignee: Nutrition 21, Inc.
    Inventor: Mark F. McCarty